PPIs are linked to a slight increase in the risk of
pancreatic cancer.
According to a study, those who take high cumulative
dosages of proton pump inhibitors (PPIs) had a slightly higher risk of
pancreatic cancer.
 |
| Image: Pancreatic Cancer | InStyleHealth |
The study included 23,321 patients with pancreatic cancer (mean age 69.8 years, 51.7 percent men) and 75,937 noncancer controls who were matched by birth, sex, frequency of hospitalization within 8 years prior to the index date, and department of residence using data from the French National Health Data System.
Diabetes mellitus, tobacco- and alcohol-related disorders
or drug use, morbid obesity, history of acute or chronic pancreatitis, and
other comorbidities such as chronic obstructive pulmonary disease were all more
common in patients than in controls. Pancreatic malignancies were most commonly
found at the head of the pancreas in the patient group, and 52.3 percent of
patients died within a year after the index date.
PPI usage documented in 18,141 patients (77.8%) and
57,307 controls (75.5%), with 43.9 percent and 37.9% of patients and controls,
respectively, redeeming prescriptions for 181 cumulative defined daily dose
(cDDD). In the sick group, the mean PPI exposure was 658.3 cDDD, while in the
control group, it was 560.8 cDDD. The most prevalent PPI was omeprazole (50.8
percent and 47.9%, respectively), followed by esomeprazole (46.0 percent and
40.6 percent, respectively).
Furthermore, PPI usage was associated with a higher
risk of pancreatic cancer than nonuse (aOR 1.05, 95 percent confidence interval
[CI], 1.01–1.09), according to multivariable conditional logistic regression
models. A dose–response association was discovered, suggesting that higher
exposure increased risk (1–30 cDDD: aOR, 0.92, 95 percent CI, 0.87–0.97; 31–180
cDDD: aOR, 1.05, 95 percent CI, 1.00–1.11; 181–1,080 cDDD: aOR, 1.18, 95
percent CI, 1.12–1.24; >1,080 cDDD: aOR, 1.17, 95 percent CI, 1.10–1.23).
Given the abuse of these medicines, the current
findings underline the necessity of efforts to confine PPI therapies to
acceptable purposes and durations.